Aurobindo finalized the acquisition of Apotex

Ten post jest także dostępny w języku: polski

In February 2019, Indian Aurobindo, through Agile Pharma, finalized the acquisition of commercial activities of Apotex International. This transaction concerns five European countries, including Poland. Its value is 74 million EUR.

The parties signed a binding acquisition agreement in July 2018. It covered products, trademarks, rights and licenses, as well as infrastructure and personnel in Poland, the Czech Republic, the Netherlands, Spain and Belgium. The closing of the transaction was subject to the approval of the antitrust authorities. In Poland, the Office of Competition and Consumer Protection (UOKiK) gave its consent in November.

The acquisition covered the portfolio of over 200 Rx drugs and 88 OTC products. The total value of sales of these products between April 2017 and March 2018 amounted to EUR 133 million. In the same period, Aurobindo’s sales in Europe amounted to EUR 577 million. Additionally, the subject of the transaction is also a portfolio of over 20 products, which will be introduced to the market within the next two years.

The acquisition of Apotex is in line with Aurobindo’s strategy implemented since 2006. It consists in the development and diversification of activities in Europe. In 2014, the company took over Actavis activities in 7 countries of Western Europe. Three years later, it acquired the Portuguese Generis Farmaceutica. In total, before the acquisition of Apotex, Aurobindo was present in 9 European countries. Now, both in Poland and the Czech Republic, the company will become one of the 15 largest manufacturers in the generic drugs segment.